Canine placenta: A promising potential source of highly proliferative and immunomodulatory mesenchymal stromal cells?

Saulnier, N.; Loriau, J; Febre, Marine; Robert, Clément; Rakic, Rodolphe; Bonte, T.; Buff, Samuel; Maddens, Stéphane

doi:10.1016/j.vetimm.2016.02.005

Cited by 32 publications

(53 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The screening of prevalent microbiological pathogens was performed from a blood sample collected from each bitch to qualify their microbiological status. Briefly, collected tissue was extensively washed with 0.9% NaCl, then submitted to mechanical and enzymatic digestion in two steps, as previously described (38). Cells were amplified in a proprietary medium in tissue culture flasks and harvested after passages 3–4.…”

Section: Methodsmentioning

confidence: 99%

“…Cells were cryopreserved and stored in a liquid nitrogen Dewar until use. Characterization of each cell product was realized as previously described (38) (Figure S1 in Supplementary Material). Briefly, cells display conventional phenotype of canine MSCs (CD44+; CD29+; CD90+; MHC2−; CD45−; CD34−), differentiate into the three mesodermal lineages in vitro (adipogenic, osteogenic, and chondrogenic), and express indoleamine 2,3-dioxygenase upon exposure to interferon-gamma stimulation (Additional file).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Effect of a Single Intra-articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells Compared to Oral Non-Steroidal Anti-inflammatory Treatment on the Postoperative Musculoskeletal Status and Gait of Dogs over a 6-Month Period after Tibial Plateau Leveling Osteotomy: A Pilot Study

Taroni

Cabon

Febre³

et al. 2017

Front. Vet. Sci.

Self Cite

View full text Add to dashboard Cite

ObjectiveCompare the clinical and pressure walkway gait evolution of dogs after a tibial plateau leveling osteotomy (TPLO) for a cranial cruciate ligament rupture (CrCLR) and treatment with either a 1-month course of non-steroidal anti-inflammatory drugs (NSAIDs) or a single postoperative intra-articular (IA) injection of allogeneic neonatal mesenchymal stromal cells (MSCs).Study designProspective, double-blinded, randomized, controlled, monocentric clinical study.AnimalsSixteen client-owned dogs.Materials and methodsDogs with unilateral CrCLR confirmed by arthroscopy were included. Allogeneic neonatal canine MSCs were obtained from fetal adnexa retrieved after C-section performed on healthy pregnant bitches. The dogs were randomly allocated to either the “MSCs group,” receiving an IA injection of MSCs after TPLO, followed by placebo for 1 month, or the “NSAIDs group,” receiving IA equivalent volume of MSCs vehicle after TPLO, followed by oral NSAID for 1 month. One of the three blinded evaluators assessed the dogs in each group before and after surgery (1, 3, and 6 months). Clinical score and gait and bone healing process were assessed. The data were statistically compared between the two groups for pre- and postoperative evaluations.ResultsFourteen dogs (nine in the MSCs group, five in the NSAIDs group) completed the present study. No significant difference was observed between the groups preoperatively. No local or systemic adverse effect was observed after MSCs injection at any time point considered. At 1 month after surgery, bone healing scores were significantly higher in the MSCs group. At 1, 3, and 6 months after surgery, no significant difference was observed between the two groups for clinical scores and gait evaluation.ConclusionA single IA injection of allogeneic neonatal MSCs could be a safe and valuable postoperative alternative to NSAIDs for dogs requiring TPLO surgery, particularly for dogs intolerant to this class of drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Evaluation of the Effect of a Single Intra-articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells Compared to Oral Non-Steroidal Anti-inflammatory Treatment on the Postoperative Musculoskeletal Status and Gait of Dogs over a 6-Month Period after Tibial Plateau Leveling Osteotomy: A Pilot Study

Taroni

Cabon

Febre³

et al. 2017

Front. Vet. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The microvesicles and exosomes are extracellular vesicles that contain cytokines and growth factors, signaling lipids, messenger RNAs, and regulatory microRNAs. These extracellular vesicles are able to bring about the paracrine effects of MSCs (Gugjoo & Amarpal, 2018;Phinney & Pittenger, 2017 Gugjoo et al, 2019;Kresic et al, 2017;Lee et al, 2013;Park et al, 2012a;Saulnier et al, 2016;Spencer et al, 2012). MSC stemness markers though are supported by a handful of genes but the molecular basis underlying these properties, especially in relation to the key transcription factors, is still poorly understood (Zheng, 2018).…”

Section: In Vivo Potential Therapeutic Applicationsmentioning

confidence: 99%

Mesenchymal stem cell basic research and applications in dog medicine

Gugjoo

Amarpal

Sharma

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

The stem cells, owing to their special characteristics like self‐renewal, multiplication, homing, immunomodulation, anti‐inflammatory, and dedifferentiation are considered to carry an “all‐in‐one‐solution” for diverse clinical problems. However, the limited understanding of cellular physiology currently limits their definitive therapeutic use. Among various stem cell types, currently mesenchymal stem cells are extensively studied for dog clinical applications owing to their readily available sources, easy harvesting, and ability to differentiate both into mesodermal, as well as extramesodermal tissues. The isolated, culture expanded, and characterized cells have been applied both at preclinical as well as clinical settings in dogs with variable but mostly positive results. The results, though positive, are currently inconclusive and demands further intensive research on the properties and their dependence on the applications. Further, numerous clinical conditions of dog resemble to that of human counterparts and thus, if proved rewarding in the former may act as basis of therapy for the latter. The current review throws some light on dog mesenchymal stem cell properties and their potential therapeutic applications.

show abstract

“…Several characteristics may make MSCs from neonatal tissues (placenta or cord-derived cells) preferable to the use of allogeneic adult tissues or postnatal tissues: (i) donors are healthy, (ii) harvest is not invasive or compromising to the animal well-being, (iii) there is low risk of biological hazard, (iv) donor age is minimized and standardized, (v) neonatal MSCs have a higher proliferation potential before replicative senescence and (vi) neonatal MSCs have a lower immunogenicity and a higher immunomodulation potential [103,104]. Moreover, standardizing source materials enables streamlining of regulatory constraints, scale-up technologies (i.e., dynamic culture systems) and automation.…”

Section: Insights From Veterinary Medicinementioning

confidence: 99%